Ayala Pharmaceuticals, Inc. (ADXS)

Ayala Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Revenue	0.01	0.69
Revenue Growth (YoY)	-98.12%	-
Cost of Revenue	0.01	0.6
Gross Profit	-	0.09
Selling, General & Admin	11.19	9.74
Research & Development	24.08	27.85
Operating Expenses	35.27	37.59
Operating Income	-35.27	-37.5
Other Non Operating Income (Expenses)	-15.72	0.07
EBT Excluding Unusual Items	-50.98	-37.43
Merger & Restructuring Charges	-1	-
Pretax Income	-51.98	-37.43
Income Tax Expense	-3.91	0.58
Net Income	-48.07	-38.01
Net Income to Common	-48.07	-38.01
Shares Outstanding (Basic)	6	3
Shares Outstanding (Diluted)	6	3
Shares Change (YoY)	107.90%	-
EPS (Basic)	-7.99	-13.13
EPS (Diluted)	-7.99	-13.13
Gross Margin	-	13.01%
Operating Margin	-271276.92%	-5419.51%
Profit Margin	-369784.61%	-5493.21%
EBITDA	-34.9	-37.34
D&A For EBITDA	0.37	0.16
EBIT	-35.27	-37.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.